Why the study?
Does ramipril reduce normal tissue radiation injury without altering tumor response to radiation in A549 cell xenografts in athymic mice?
Does ramipril reduce normal tissue radiation injury without altering tumor response to radiation in A549 cell xenografts in athymic mice?
Ramipril mitigates radiation-induced normal tissue injury without protecting tumors, suggesting a potential therapeutic gain in radiotherapy.
Supports ramipril radioprotection in xenografts without tumor shielding; leaves open clinical translation and therapeutic gain.
Kohl, R. R., Kolozsvary, A., Brown, S. L., Zhu, G. and Kim, J. H. Differential Radiation Effect in Tumor and Normal Tissue after Treatment with Ramipril, an Angiotensin-Converting Enzyme Inhibitor. Radiat. Res. 168, 440–445 (2007).The angiotensin-converting enzyme inhibitor, ramipril, has been shown to mitigate radiation injury in normal tissues. Using A549 cell xenografts grown in athymic mice, we measured the effect of ramipril on radiation damage to tumors. Ramipril did not alter tumor response to radiation despite different times of drug administration with respect to radiation delivery (drug started 2 weeks before or immediately after irradiation). In contrast, using the same dose, ramipril reduced normal tissue radiation injury (30 Gy × 2 or 6 Gy × 10) as assessed by a semi-quantitative scale of skin damage and relative leg contraction. The results indicate that ramipril could offer therapeutic gain due to its different effect on normal tissues and tumors.
No takes yet. Share an insight, caveat, or question.
Kohl et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: